The Effect of Bevacizumab Therapy on Reducing Erythrocyte Transfusion Requirements and Preventing Iron Deficiency in Patients With Hereditary Hemorrhagic Telangiectasia | Synapse
March 3, 2026Open Access
The Effect of Bevacizumab Therapy on Reducing Erythrocyte Transfusion Requirements and Preventing Iron Deficiency in Patients With Hereditary Hemorrhagic Telangiectasia
Statistical analysis revealed notable improvements in iron parameters over the treatment period.
Observational analysis across multiple centers measured the impact of IV bevacizumab on HHT-related bleeding.
This finding supports the effectiveness of bevacizumab for managing transfusion needs and iron deficiency.
Abstract
In this multicenter retrospective cohort, IV bevacizumab therapy was associated with improved iron parameters and reduced transfusion requirements in patients with HHT-related bleeding.